recombinant human endostatin
Trials 27
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01310478 | Aug 2010 → May 2011 | colorectal neoplasm | Fudan University | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01733589 | Nov 2012 → Jun 2015 | non-small cell lung carcinoma | Zhejiang Cancer Hospital | Completed | No outcome recorded |
| Phase 216 trials · 1 met primary | ||||||
| Phase 2 | NCT06059261 | Feb 2026 → Feb 2027 expected | nasopharyngeal carcinoma | Chongqing University Cancer Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06747169 | Dec 2024 → Dec 2026 expected | non-small cell squamous lung carcinoma | Jian-Guo Zhou, MD, PhD | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06618391 | Oct 2024 → Mar 2026 overdue | non-small cell lung carcinoma | Henan Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06611826 | Sep 2024 → Sep 2028 expected | nasopharyngeal carcinoma | Zhejiang Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06617936 | Aug 2024 → Sep 2026 overdue | non-small cell lung carcinoma | Hua Zhang | Recruiting | No outcome recorded |
| Phase 2 | NCT06279754 | Feb → Jun 2024 | non-small cell squamous lung carcinoma | The First Affiliated Hospital of Xinxiang Medical College | Unknown | No outcome recorded |
| Phase 2 | NCT06041724 | Sep 2023 → Sep 2025 | mucosal melanoma | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT05278715 | Apr 2022 → Dec 2025 overdue | childhood optic nerve glioma | Beijing Sanbo Brain Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05243355 | Dec 2021 → Dec 2023 | non-small cell squamous lung carcinoma | Qilu Hospital of Shandong University | Unknown | No outcome recorded |
| Phase 2 | NCT04659421 | Nov 2020 → Jul 2023 | brain neoplasm, low grade glioma | Beijing Sanbo Brain Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04267978 | Feb 2020 → Dec 2025 overdue | glioblastoma, low grade glioma | Beijing Sanbo Brain Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT03989830 | Jul 2019 → Jun 2021 | head and neck neoplasm | Sun Yan | Unknown | No outcome recorded |
| Phase 2 | NCT03622827 | Jul 2018 → Jul 2023 | cervical cancer | Nanjing Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT03208335 | Jan 2017 → Dec 2018 | hepatocellular carcinoma | Chinese PLA General Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03095079 | Oct 2016 → Dec 2017 | melanoma | Peking University Cancer Hospital & Institute | Unknown | Met primary |
| Phase 2 | NCT02005120 | Dec 2013 → Dec 2015 | non-small cell lung carcinoma | Zhejiang University | Unknown | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT03577392 | Jul 2018 → Aug 2019 | — | Sichuan Provincial People's Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT02350361 | Jan 2014 → Jul 2015 | lung cancer | Peking University Third Hospital | Unknown | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT03008109 | Feb → Nov 2017 | cancer of unknown primary site, non-small cell lung carcinoma | Zaiwen Fan | Unknown | No outcome recorded |
| Phase 3 | NCT00657423 | Apr → Dec 2008 | lung neoplasm | Xijing Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT01124253 | Jul 2007 → Oct 2009 | non-small cell lung carcinoma | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT04613284 | Dec 2020 → Feb 2022 | lung cancer | Shanghai Chest Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04356118 | Jun 2020 → Jun 2023 | malignant leptomeningeal tumor | Hui Bu | Unknown | No outcome recorded |
| Phase 4 | NCT02804646 | Jun 2016 → Dec 2017 | lung adenocarcinoma | Anhui Provincial Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01211002 | Oct 2010 → Dec 2011 | non-small cell lung carcinoma | Simcere Pharmaceutical Co., Ltd | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00576914 Comparator | Jun 2007 → Jun 2012 | non-small cell lung carcinoma | Chinese Academy of Sciences | Unknown | No outcome recorded |
Press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-07-28 | Jiangsu Simcere Pharmaceutical Co., Ltd. | COSELA® and Endostar® Receive Endorsement in Chinese Medical Association's Lung Cancer Treatment Guidelines simcere.com ↗ |
| 2022-06-07 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Latest Clinical Data regarding ENDOSTAR and Trilaciclib Presented at the 2022 ASCO simcere.com ↗ |
| 2021-05-26 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Simcere Will Announce Progress of Multiple Clinical Research on Antitumor Drugs at the 2021 ASCO Annual Meeting Endostar®（Recombinant Human Endostatin Injection） Envafolimab (KNO35) simcere.com ↗ |
| 2018-04-25 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Endostar included in CSCO Guidelines on the Diagnosis and Treatment simcere.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 29 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant human endostatin | “This study is aim to observe the safety and efficacy of the combination of an anti-angiogenic drug recombinant human-endostatin with EGFR TKI ,to find out a new strategy which...” NCT03008109 ↗27“The dose of Recombinant human endostatin on day -5 was calculated according to the patients's body surface area, to provide a CIV 7 days' dose in physiological saline to 240mL volume.” NCT03577392 ↗ “Endostar: recombinant human endostatin (15mg/m2/d, civ, d1-7) is given 3 days before the concurrent chemoradiotherapy for 2 cycles every 3 weeks.” NCT03622827 ↗ “Recombinant human endostatin (rh-ES) is an endogenous broad-spectrum angiogenesis inhibitor” NCT04659421 ↗ “recombinant human endostatin given intravenously,7.5mg/㎡,d1-14,2cycles.” NCT00657423 ↗ |
| Known as | Endostar | “Endostar is a recombinat human endostatin with antiangiogenic properties that has been useful in treating a wide range of cancers and shows promise for use in combination...” NCT03577392 ↗6“This phase II trial evaluated the efficacy and safety of a soluble and stable rhES (Endostar) plus dacarbazine in patients with metastatic melanomas that contains no mutations...” PMID 23670576 ↗ May 2013 “Endostar: recombinant human endostatin (15mg/m2/d, civ, d1-7) is given 3 days before the concurrent chemoradiotherapy for 2 cycles every 3 weeks.” NCT03622827 ↗ “A Prospective, Singal-arm Clinical Study of Recombinant Human Endostatin (ENDOSTAR) Combined With Carboplatin and Vincristine” NCT04659421 ↗ “Recombinant Human Endostatin Injection (Endostar),210mg was pumped intravenously for 3 consecutive days” NCT06617936 ↗ “Recombinant human endostatin（Endostar）：15mg，d1-14, intravenous injection.” NCT01211002 ↗ “Recombinant human endostatin (Endostar)” NCT04613284 ↗ |
| Known as | Endostat | “recombinant human endostatin (Endostat)” NCT01310478 ↗ |
| Known as | Recombinant Human Endostatin Injection | “Recombinant Human Endostatin Injection：210 mg, intravenous infusion for 72 hours, once every three weeks cycle” NCT06279754 ↗ |
| Known as | rh-endostatin | “Continuous intravenous pumping (CIP) recombinant human endostatin(rh-endostatin) 30mg/d” NCT03208335 ↗ |
| Known as | rh-ES | “However, efficacy of recombinant human endostatin (rhES) in clinical trials is controversial, and application of rhES in treatment of metastatic melanoma awaits further investigations.” PMID 23670576 ↗ May 20133“Recombinant human endostatin (rh-ES) is administrated at a dose of 15mg daily, for 14 consecutive days every 3 weeks.” NCT05278715 ↗ “Recombinant human endostatin (rh-ES) is an endogenous broad-spectrum angiogenesis inhibitor” NCT04659421 ↗ “Recombinant human endostatin (rh-ES) is an endogenous broad-spectrum angiogenesis inhibitor” NCT04267978 ↗ |
| Action | Inhibit | “Endostatin is a potent endogenous angiogenic inhibitor with implicated antitumor activity.” PMID 23670576 ↗ May 2013 |
| Modality | Protein / enzyme biologic | “recombinant human endostatin” NCT00576914 ↗ |
| Route | Intravenous | “7.5mg/m2 IV (in the vein)” NCT00576914 ↗ |